Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

Guardant Health director Alex Azar II sells $10,319 in shares

Guardant Health director Alex Azar II sells $10,319 in shares

Guardant Health's director, Alex Azar II, sold 69 shares of the company's stock on November 16, 2026, for a total of $10,319. The current stock price sits at $143.28, reflecting a 51% increase over the past six months. Despite this gain, analysts suggest Guardant Health may be overvalued. Following his sale, Mr. Azar II retains 962 shares of the company's common stock.

Pro Tips from InvestingPro indicate that the company's stock is highly volatile and is not projected to be profitable this year. Investors looking for more detailed analysis can access Guardant Health's Pro Research Report. Recently, the company reported a strong third quarter, with revenue increasing 36% to $361 million, surpassing analyst expectations.

Despite this positive earnings report, Guardant Health saw a selloff as investors worried about increased cash burn and heavy spending. BTIG maintained its Buy rating for Guardant Health, targeting a price of $210.00, following the earnings report. The firm highlighted a 3% revenue beat and an upward revision in the company's 2026 revenue guidance.

These developments suggest Guardant Health is experiencing growth in its oncology, screening, and biopharma segments.

Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

Read the original at investing.com →